Abstract: Neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, are heavily characterized by enhanced neuronal apoptosis and mitochondrial dysfunction. The voltage-dependent anion channel 1 (VDAC1), located at the outer mitochondrial membrane, plays a pivotal role in mitochondrion-mediated apoptosis through its oligomerization, which facilitates the release of apoptogenic proteins like cytochrome c. VBIT-4 is a novel, small-molecule inhibitor specifically developed to target VDAC1. By directly interacting with VDAC1, VBIT-4 prevents its oligomerization, thereby inhibiting apoptosis and protecting against mitochondrial dysfunction. Furthermore, VBIT-4 prevents the detachment of mitochondria-bound hexokinase (HK), a pathological event linked to several neurodegenerative disorders. With demonstrated efficacy in preventing apoptotic cell death, restoring mitochondrial membrane potential, and reducing reactive oxygen species (ROS) and calcium accumulation without exhibiting in vivo toxicity, VBIT-4 represents a highly promising therapeutic candidate for the treatment of neurodegenerative diseases.
1. Introduction
Apoptosis plays a critical role in the pathogenesis of several neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In the brains of patients suffering from these conditions, dying neurons frequently display morphological features of apoptosis, such as chromatin condensation, DNA fragmentation, and the activation of caspases [1]. A central convergence point for cell death signals is the mitochondria, specifically the voltage-dependent anion channel 1 (VDAC1) located at the outer mitochondrial membrane (OMM) [1]. During apoptosis, VDAC1 undergoes oligomerization to form a large flexible pore that allows the release of pro-apoptotic proteins, such as cytochrome c (Cyto c) and apoptosis-inducing factor (AIF), from the mitochondrial intermembrane space into the cytosol [1]. Because VDAC1 oligomerization is an early and essential step in this intrinsic apoptotic pathway, it represents a prime pharmacological target. VBIT-4 is a novel drug candidate developed through high-throughput screening and medicinal chemistry to specifically interact with VDAC1, inhibit its oligomerization, and halt the apoptotic cascade, offering a targeted therapeutic strategy for neurodegenerative disorders [1].
2. Pharmacological Activity
VBIT-4 exhibits potent anti-apoptotic and neuroprotective pharmacological activities. In in vitro studies, VBIT-4 successfully inhibited apoptosis induced by various agents, including selenite, cisplatin, and staurosporine (STS), across multiple cell lines, notably including the neuroblastoma cell line SH-SY5Y [1]. Beyond merely halting cell death, VBIT-4 protects against apoptosis-associated mitochondrial dysfunction. It prevents the dissipation of the mitochondrial membrane potential ($\Delta\Psi_m$), thereby maintaining cellular energy and metabolism [1]. Additionally, VBIT-4 completely prevents the elevation of intracellular calcium levels ($Ca^{2+}$) and the subsequent accumulation of calcium in the mitochondria, which are typical triggers for mitochondrial collapse [1]. The compound also effectively inhibits the generation of both cellular and mitochondrial reactive oxygen species (ROS) [1]. Importantly, VBIT-4 demonstrates a favorable safety profile; it had no adverse effects on normal cell growth and viability, and mice exposed to the compound for four months exhibited no signs of toxicity in terms of weight, behavior, or organ histochemistry [1].
3. Molecular Mechanism of Action
The primary mechanism of action of VBIT-4 involves its direct interaction with VDAC1. By binding to VDAC1, VBIT-4 prevents the protein from shifting from a monomeric state to an oligomeric state [1]. This inhibition of oligomerization directly blocks the formation of the large pore required for the transit of Cyto c across the OMM, thereby arresting the apoptotic pathway at an early stage [1]. Furthermore, VBIT-4's action is independent of the pro-apoptotic Bax and Bak proteins, as it remains effective in inhibiting VDAC1 oligomerization and Cyto c release in Bax/Bak-lacking cells [1].
Another crucial aspect of VBIT-4's mechanism is its ability to inhibit the detachment of hexokinase (HK) from the mitochondria. Under normal conditions, VDAC1-bound HK couples cytosolic glycolysis to mitochondrial oxidative phosphorylation and prevents the release of pro-apoptotic factors. Apoptotic stimuli typically induce the dissociation of the VDAC1-HK complex. VBIT-4 strongly inhibits this HK detachment, suggesting that HK detachment is associated with VDAC1 oligomerization, and by preventing the latter, VBIT-4 maintains the protective HK-VDAC1 interaction [1].
4. Structure-Activity Relationship (SAR)
VBIT-4 was developed following three rounds of structure-activity relationship (SAR) studies, originating from a commercially available hit compound, AKOS-022 [1]. To synthesize VBIT-4, the piperazine ring of AKOS-022 was conjugated with an aniline moiety, and the central pyrrolidine-2,5-dione rigid ring was linearized into a 4-hydroxybutanamide moiety [1]. This specific structural modification makes VBIT-4 more flexible (due to the linear moiety versus a cyclic group) and more hydrophilic (alcohol versus amide) compared to its analogs like VBIT-3 [1]. This increased flexibility is critical for its ability to interfere with the protein-protein interactions necessary for VDAC1 oligomerization. Although VBIT-4 is a chiral molecule, both of its separated enantiomers (R and S conformations) display identical activity in inhibiting VDAC1 oligomerization and apoptosis. This indicates that the flexible VBIT-4 molecule interferes with VDAC1 monomer interactions in regions that are widely accessible to both enantiomeric conformations [1].
5. Current Limitations
While VBIT-4 is highly effective against most tested apoptotic inducers, it exhibited an anomalous response when apoptosis was induced by arsenic trioxide ($As_2O_3$). Instead of inhibiting cell death, the addition of VBIT-4 slightly enhanced $As_2O_3$-induced apoptosis [1]. This suggests that $As_2O_3$ may operate through molecular targets or mechanisms (such as direct binding to promyelocytic leukemia proteins or interaction with sulfhydryl groups) that are not mitigated, or are perhaps exacerbated, by the inhibition of VDAC1 oligomerization [1]. Additionally, in vitro binding assays revealed that VBIT-4 binds to recombinant purified VDAC isoforms with an affinity approximately 3-fold lower than its affinity for native VDAC1 purified from rat liver mitochondria. This discrepancy is likely due to the unfolding and refolding processes required for recombinant proteins, which may result in modified conformations that slightly hinder VBIT-4 binding [1].
6. Future Perspectives
The development of VBIT-4 opens significant therapeutic avenues for neurodegenerative diseases. Pathological conditions such as Parkinson's disease, Alzheimer's disease, and schizophrenia have been directly linked to the detachment of HK from mitochondria and the overexpression of VDAC, which leads to spontaneous oligomerization and neuronal apoptosis [1]. Because VBIT-4 specifically interacts with VDAC1 to inhibit both its oligomerization and the subsequent HK detachment, it directly counteracts these exact pathological mechanisms. Future research should focus on in vivo models of Alzheimer's and Parkinson's diseases to evaluate the blood-brain barrier permeability of VBIT-4 and its long-term efficacy in halting neurodegeneration and preserving cognitive and motor functions [1].
